跳转至内容
Merck
所有图片(1)

文件

SML1051

Sigma-Aldrich

比伐卢定 三氟乙酸盐

≥97% (HPLC)

别名:

Hirulog 三氟乙酸盐, 三氟醋酸比伐卢定

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C98H138N24O33 · xC2HF3O2
CAS号:
128270-60-0
分子量:
2180.29 (free base basis)
分類程式碼代碼:
51111800
NACRES:
NA.77

化驗

≥97% (HPLC)

形狀

powder

顏色

white to off-white

運輸包裝

wet ice

儲存溫度

−20°C

InChI

1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1

InChI 密鑰

OIRCOABEOLEUMC-GEJPAHFPSA-N

生化／生理作用

比伐卢定三氟乙酸盐是由20个氨基酸组成的合成肽。它可作为抗凝剂，用于经冠状动脉成形术的患有不稳定型心绞痛患者。
比伐卢定是一种特异性且可逆的二价直接凝血酶抑制剂。比伐卢定与凝血酶（循环的和凝块结合的)的催化位点和阴离子结合的外位点均有特异性结合。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 3

1 of 3

戊二醛 溶液 Grade I, 70% in H2O, specially purified for use as an electron microscopy fixative or other sophisticated use

Sigma-Aldrich

G7776

戊二醛 溶液

L -胱氨酸 ≥98% (TLC), crystalline

Sigma-Aldrich

C8755

L -胱氨酸

vibrant-m

H0200000

肝素 钠

Mahesh V Madhavan et al.
The American journal of cardiology, 114(9), 1322-1328 (2014-09-23)
Postprocedural anticoagulation (AC) after primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) may be administered for a number of specific therapeutic indications (e.g. atrial fibrillation or left ventricular thrombus). However, the safety and effectiveness of such post-PCI
Marco Valgimigli et al.
The New England journal of medicine, 373(11), 997-1009 (2015-09-02)
Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome. We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated
Aakriti Gupta et al.
The American journal of cardiology, 116(1), 1-7 (2015-05-06)
Excess dosing of anticoagulant agents has been linked to increased risk of bleeding after percutaneous coronary intervention (PCI) for women compared with men, but these studies have largely included older patients. We sought to determine the prevalence and gender-based differences
Karolina Szummer et al.
JAMA, 313(7), 707-716 (2015-02-18)
Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in
Liquid chromatography method for determination of bivalirudin in human plasma and urine using automated ortho-phthalaldehyde derivatization and fluorescence detection.
Farthing D, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 802(2), 355-359 (2004)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门